Cervical Cancer Vaccines Market, By Product Type (Cervarix, Gardasil, and Gardasil 9), By Distribution Channel (Hospitals, Clinics, and Government Entities), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast 2018 - 2026

  • Published On : Jul 2019 |
  • Pages : 145 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Cervical Cancer Vaccines Market – Insights

Cervical cancer is currently the leading cause of cancer mortality among women worldwide. According to World Health Organization 2018, around 90% of deaths from cervical cancer occurred in low- and middle-income countries. Human papillomavirus (HPV) vaccination has the potential to substantially decrease this burden. The U.S. Food and Drug Administration has approved three vaccines including Cervarix, Gardasil, and Gardasil 9 that aid in preventing HPV infections, which are leading causes of cervical cancer.

The cervical cancer vaccines market size was valued at US$ 2,595.4 million in 2018, and is expected to witness a CAGR of 12.1% over the forecast period (2018 – 2026).

Global Cervical Cancer Vaccines Market (%) Analysis, By Product Type, 2018

Cervical Cancer Vaccines  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing Government Initiatives and Programs to Augment Growth of the Cervical Cancer Vaccines Market

Major governments around the world are focused on taking initiatives to increase awareness among the populace regarding cervical cancer and its treatments. Favorable government initiatives such as free vaccination is also driving growth of the global cervical cancer vaccines market. For instance, according to American Society of Clinical Oncology (ASCO) 2018, the government of Rwanda aims to eradicate cervical cancer by 2020 by immunizing all adolescent girls between 11 and 15 years of age.

Cervical Cancer Vaccines Market - Restraints

High cost associated with the treatment of cervical cancer is expected to hamper growth of the global cervical cancer vaccines market during the forecast period. For instance, according to National Center for Biotechnology Information (NCBI) 2017, the cost of cervical cancer treatment ranged from US$ 368 – US$ 11,400 depending on the type of hospital and treatment involved. HPV vaccination is likely to be very cost-effective with an incremental cost per disability-adjusted life year (DALY) averted in the range US$ 780 – US$ 1,120. However, under list prices for Cervarix and Gardasil in Vietnam, the incremental cost per DALY averted for HPV vaccination can exceed US$ 8000.

Cervical Cancer Vaccines Market - Regional Insights

On the basis of region, the global cervical cancer vaccines market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global cervical cancer vaccines market during the forecast period, owing to increasing prevalence of cervical cancer in the U.S. For instance according to National Cancer Institute, 2016, around 289,696 women were suffering from cervical cancer in the U.S. in 2016. Moreover, according to the American Cancer Society’s estimates, around 13,170 new cases of invasive cervical cancer will be diagnosed and 4,250 death of women will be registered from cervical cancer in the U.S. in 2019.

Asia Pacific is expected to foresee a rapid growth in the cervical cancer vaccines market. The market in Asia Pacific is expected to gain momentum during the forecast period, owing to increasing approval of cervical cancer vaccines by the regulatory bodies. For instance, in 2016, China Food and Drug Administration (CFDA) approved Cervarix as the first HPV vaccine licensed for use in China against cervical cancer to meet the unmet needs of prevention of cervical cancers among Chinese population. According to National Center for Biotechnology Information 2018, China being the world’s largest developing country, exhibits a high incidence of cervical cancer with approximately 130,000 new cases each year.

Global Cervical Cancer Vaccines Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2026

   Cervical Cancer Vaccines  | Coherent Market Insights

 Source: Coherent Market Insights Analysis (2019)

Cervical Cancer Vaccines Market - Competitive Landscape

Key players operating in the cervical cancer vaccines market include, GlaxoSmithKline PLC and Merck & Co. Inc.

Cervical cancer is a common type of cancer occurring in women worldwide. A major cause of cervical cancer is infection by human papillomavirus (HPV), which is found in 99% cervical cancer. Human papillomavirus is sexually transmitted. Around 100 types of HPV have been identified to date, of which types 16 and 18 are believed to be responsible for more than 70% of cervical cancers. Cervarix and Gardasil are type of vaccines used for the treatment of cervical cancer.

Market Dynamics

Increasing prevalence of cervical cancer worldwide is expected to boost the cervical cancer vaccines market growth. According to the World Health Organization (WHO), 2018, cervical cancer is the fourth most frequent cancer in women with an estimated 570,000 new cases and representing 6.6% of all female cancers worldwide and around 85% of deaths occur due to cervical cancer in developing countries.

However, lack of awareness amongst the people in the low-income and middle-income countries regarding cervical cancer is expected to hinder growth of the cervical cancer vaccines market during the forecast period. Cervical cancer is one of the most common cancers among women of reproductive age in low-income and middle-income countries. For instance, according to The International Agency for Research on Cancer’s (IARC) report of 2013, cervical cancer is most notable in low-income countries of sub-Saharan Africa.

Key features of the study:

  • This report provides in-depth analysis of the global cervical cancer vaccines market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2026, considering 2018 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the cervical cancer vaccines market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, GlaxoSmithKline plc. and Merck & Co. Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The cervical cancer vaccines market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for immune repertoire sequencing market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Cervical Cancer Vaccines Market , By Product Type:
    • Gardasil
    • Gardasil 9
    • Cervarix
  • Global Cervical Cancer Vaccines Market, By Distribution Channel:
    • Hospitals
    • Clinics
    • Government Entities
  • Global Cervical Cancer Vaccines Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Product Type:
        • Gardasil
        • Gardasil 9
        • Cervarix         
      • By Distribution Channel:
        • Hospitals
        • Clinics
        • Government Entities
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Product Type:
        • Gardasil
        • Gardasil 9
        • Cervarix
      • By Distribution Channel:
        • Hospitals
        • Clinics
        • Government Entities
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Product Type:
        • Gardasil
        • Gardasil 9
        • Cervarix
      • By Distribution Channel:
        • Hospitals
        • Clinics
        • Government Entities
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Product Type:
        • Gardasil
        • Gardasil 9
        • Cervarix
      • By Distribution Channel:
        • Hospitals
        • Clinics
        • Government Entities
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Product Type:
        • Gardasil
        • Gardasil 9
        • Cervarix         
      • By Distribution Channel:
        • Hospitals
        • Clinics
        • Government Entities
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Product Type:
        • Gardasil
        • Gardasil 9
        • Cervarix         
      • By Distribution Channel:
        • Hospitals
        • Clinics
        • Government Entities
  • Company Profiles
    • GlaxoSmithKline plc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Merck & Co. Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Landscape
    • Product Recall
    • Epidemiology Analysis
    • Technology Overview
    • PEST Analysis
    • Porter’s Five Forces Model
  4. Global Cervical Cancer Vaccines Market , By Product Type, 2019 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Gardasil
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Gardasil 9
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Cervarix
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
  5. Global Cervical Cancer Vaccines Market, By Distribution Channel, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Clinics
      • Introduction  
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
    • Government Entities
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
  6. Global Cervical Cancer Vaccines Market, By Region, 2018 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Product Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Product Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Product Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Product Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, Distribution Channel, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2018 – 2026, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Product Type, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  7. Competitive Landscape
    • Company Profiles
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Merck & Co. Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 23 market data tables and 21 figures on "Cervical Cancer Vaccines Market” - Global forecast to 2026”

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.